N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar… - The Lancet, 2018 - thelancet.com
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs …
World Health Organization - 2022 - books.google.com
The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug- Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …
Objective: To compare the effectiveness of second line injectables containing shorter (duration 9–12 months) and longer treatment regimens (LTR, duration≥ 20 months) among …
Executive summary Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to treat than drug-susceptible ones, and threaten global progress towards the targets set by …
P Nahid, SR Mase, GB Migliori, G Sotgiu… - American journal of …, 2019 - atsjournals.org
Background: The American Thoracic Society, US Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America …
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia …
The WHO treatment guidelines for drug-resistant tuberculosis, 2016 update aims to support health professionals worldwide to respond to the continued challenge posed by …
Executive summary Tuberculosis can be treated, prevented, and cured. Rapid, sustained declines in tuberculosis deaths in many countries during the past 50 years provide …
Z Lan, N Ahmad, P Baghaei, L Barkane… - The Lancet …, 2020 - thelancet.com
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a combination of multiple second-line drugs. These drugs are associated with numerous …